Services contract with Joslin and Pharma Partner

LONDON and NEW YORK, 29 July 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that it has been contracted to undertake a biomarker research and precision diagnostics programme with Joslin Diabetes Center ("JDC") and a leading global pharmaceutical company. This development work has begun on a completed phase 3 GLP-1 agonist clinical trial targeting management of blood sugar levels in people with Type 2 diabetes.

Under the contract, Renalytix will examine the clinical utility of 21 circulating proteins that are most strongly associated with progression to end-stage kidney disease. This panel of proteins, when measured on the Olink Proximity Extension Assay (PEA) proteomics platform, are collectively referred to as the Joslin Kidney Panel (JKPTM). The data generated will inform strategy for future drug clinical trials. Results are expected to be published in 2026.

Renalytix has agreed exclusive access with JDC for the use of the proprietary JKPTM which has been shown to have a wide range of potential applications including prognosis of Cardiovascular and Kidney disease progression, prediction of drug response and monitoring of impact of care.

Renalytix believes this proprietary technology significantly expands the Renaltyix services offering to Pharma for Proteomics Biomarker Research and Development and has substantial services revenue value from supporting current and next generation pharmaceutical drug development and commercial programmes in Cardiovascular, Renal and Metabolic Diseases (CVRM).

Fergus Fleming, Chief Technology Officer of Renalytix said: "Today's announcement is a significant milestone in our journey to bring precision diagnostics solutions to patients with chronic disease and is built on years of world class research from the laboratory of our long-time collaborator, Prof. Andrzej Krolewski at the Joslin Diabetes Center. Having developed and implemented kidneyintelX.dkd as the first precision diagnostic test in chronic kidney disease and having seen the golden age of new therapies coming to market in recent years, we now set our sights on the next wave of innovation where we believe the role of novel biomarkers in clinical practice will be pivotal to delivering the best possible outcomes for patients with Diabetes and its complications including Kidney and Cardiovascular disease. This expansion of our multi-modal precision medicine platform will accelerate the rate of data generation with Pharma and Academic partners necessary to fuel product development and clinical adoption of precision medicine in Chronic Disease."

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Part of Beth Israel Lahey Health, Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. Joslin develops and disseminates innovative patient therapies and scientific discoveries throughout the world. A part of Beth Israel Lahey Health, Joslin is affiliated with Harvard Medical School and one of only 18 NIH-designated Diabetes Research Centers in the United States.